The Hunterbrook report, which prompted the sudden market drop, claims The Ensign Group’s profitability stems from a business model built on understaffing and the manipulation of quality metrics. The investigation seeks to determine if shareholders suffered financial losses due to these allegedly deceptive practices, which Hunterbrook contends resulted in inadequate patient care and fatalities.

Rosen Law is currently organizing a class action lawsuit to recover losses for investors who purchased shares before the disclosure. Phillip Kim, an attorney at the firm, is managing the outreach for potential participants. The firm asserts that its history of litigating securities claims distinguishes its approach from other entities currently issuing similar shareholder notices. Investors can register their interest via the firm's website or contact their New York office directly to discuss the criteria for the prospective litigation.